Latest Leverage News

Merino & Co. has landed a significant A$300,000 domestic purchase order, marking a key step in its strategy to rebuild and strengthen its Australian wholesale channels while balancing international growth.

NOVONIX Limited posted a $92.7 million net loss for 2025 while progressing its synthetic graphite anode materials business and preparing to divest its Battery Technology Solutions segment.

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.

Pengana Private Equity Trust reported a significant decline in half-year profit for the period ending 31 December 2025, yet increased its interim distribution to unitholders. The Trust’s net asset value per unit showed a modest rise despite challenging market conditions.

StepChange Holdings Limited reports a strong half-year performance post-IPO, with $24.36 million in revenue and a net profit of $524,400, underpinned by key acquisitions and US expansion.

Bapcor Limited reported a statutory loss of $104.8 million for the first half of FY26 and announced a fully underwritten $200 million equity raising to strengthen its balance sheet and support operational recovery.

TZ Limited reported a $1.92 million loss for the half-year ending December 2025, with revenues of $5.4 million impacted by delayed US projects and integration challenges from its Keyvision acquisition. The company is banking on large tenders and expanding Microsoft data centre sales to drive recovery.

Rincon Resources has uncovered a significantly larger gold-copper mineralised zone at its Telfer South project, extending the known strike to over 1km with exceptional historic grades. This discovery sets the stage for a major drilling campaign aimed at expanding the resource base.

NTAW Holdings reported a reduced half-year loss of $9.7 million on a 12.3% revenue decline, driven by operational challenges and brand distribution changes. The company is focusing on cost restructuring and strategic partnerships to restore growth.

Bapcor Limited reported a statutory loss of $104.8 million for the first half of FY26, alongside an underlying profit in line with guidance. The company announced a $200 million equity raising to strengthen its balance sheet and fund a strategic turnaround.

Neurizon Therapeutics has commenced dosing in a major Phase 2/3 trial of its lead drug NUZ-001 for ALS, marking a critical step in advancing treatment options for this devastating disease.

Qoria Limited reported a 25% revenue increase to nearly $69 million for H1 FY2026 but also a widening net loss of $24.5 million. The company announced a transformative merger with US-based Aura to create a global digital safety leader.